68 related articles for article (PubMed ID: 21872966)
1. Identification of distant drug off-targets by direct superposition of binding pocket surfaces.
Schumann M; Armen RS
PLoS One; 2013; 8(12):e83533. PubMed ID: 24391782
[TBL] [Abstract][Full Text] [Related]
2. Structure-based systems biology for analyzing off-target binding.
Xie L; Xie L; Bourne PE
Curr Opin Struct Biol; 2011 Apr; 21(2):189-99. PubMed ID: 21292475
[TBL] [Abstract][Full Text] [Related]
3. Sequence-based drug design as a concept in computational drug design.
Chen L; Fan Z; Chang J; Yang R; Hou H; Guo H; Zhang Y; Yang T; Zhou C; Sui Q; Chen Z; Zheng C; Hao X; Zhang K; Cui R; Zhang Z; Ma H; Ding Y; Zhang N; Lu X; Luo X; Jiang H; Zhang S; Zheng M
Nat Commun; 2023 Jul; 14(1):4217. PubMed ID: 37452028
[TBL] [Abstract][Full Text] [Related]
4. Molecular drug targets and structure based drug design: A holistic approach.
Singh S; Malik BK; Sharma DK
Bioinformation; 2006 Dec; 1(8):314-20. PubMed ID: 17597912
[TBL] [Abstract][Full Text] [Related]
5. Design of Protein Segments and Peptides for Binding to Protein Targets.
Gupta S; Azadvari N; Hosseinzadeh P
Biodes Res; 2022; 2022():9783197. PubMed ID: 37850124
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding at the protein-lipid interface: strategic considerations for drug design.
Payandeh J; Volgraf M
Nat Rev Drug Discov; 2021 Sep; 20(9):710-722. PubMed ID: 34257432
[TBL] [Abstract][Full Text] [Related]
7. Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound.
Garcia PK; Annamalai T; Wang W; Bell RS; Le D; Martin Pancorbo P; Sikandar S; Seddek A; Yu X; Sun D; Uhlemann AC; Tiwari PB; Leng F; Tse-Dinh YC
PLoS One; 2019; 14(2):e0207733. PubMed ID: 30794538
[TBL] [Abstract][Full Text] [Related]
8. Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.
Currin A; Swainston N; Day PJ; Kell DB
Chem Soc Rev; 2015 Mar; 44(5):1172-239. PubMed ID: 25503938
[TBL] [Abstract][Full Text] [Related]
9. Stable isotope dilution mass spectrometry for membrane transporter quantitation.
Farrokhi V; McShane AJ; Nemati R; Yao X
AAPS J; 2013 Oct; 15(4):1222-31. PubMed ID: 24022320
[TBL] [Abstract][Full Text] [Related]
10. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
11. Structure-based computational analysis of protein binding sites for function and druggability prediction.
Nisius B; Sha F; Gohlke H
J Biotechnol; 2012 Jun; 159(3):123-34. PubMed ID: 22197384
[TBL] [Abstract][Full Text] [Related]
12. Binding sites in membrane proteins--diversity, druggability and prospects.
Adams R; Worth CL; Guenther S; Dunkel M; Lehmann R; Preissner R
Eur J Cell Biol; 2012 Apr; 91(4):326-39. PubMed ID: 21872966
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Chemogenomics in drug discovery: computational methods based on the comparison of binding sites.
Vulpetti A; Kalliokoski T; Milletti F
Future Med Chem; 2012 Oct; 4(15):1971-9. PubMed ID: 23088277
[TBL] [Abstract][Full Text] [Related]
15. Predicting protein druggability.
Hajduk PJ; Huth JR; Tse C
Drug Discov Today; 2005 Dec; 10(23-24):1675-82. PubMed ID: 16376828
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
